AbbVie Inc.

AbbVie Inc. is a research-based biopharmaceutical company that develops, manufactures, commercializes, and sells medicines and therapies globally. Its portfolio includes treatments for autoimmune diseases such as Skyrizi and Rinvoq; blood cancers like Imbruvica, Venclexta, and Epkinly; various cancers including Elahere and Emrelis; and neurological conditions such as Vraylar for schizophrenia and bipolar disorder, Duodopa for Parkinson's disease, and Botox Therapeutic for chronic migraine and other conditions. AbbVie also offers aesthetic products like Botox Cosmetic and Juvederm Collection for facial injectables and body contouring, as well as eye care products including Lumigan/Ganfort and Restasis, and Mavyret for hepatitis C. Additionally, it provides Creon for pancreatic enzyme replacement.

AbbVie Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol ABBV. Its financial reporting and stock trading are conducted in US Dollars (USD). As a US-based company, AbbVie's shares are traded in the US market, and investors typically transact in USD. The company's primary listing is on the NYSE, one of the world's largest stock exchanges, providing liquidity and exposure to global investors.

AbbVie Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. This classification reflects its core business of developing and manufacturing pharmaceutical drugs and therapies. As a drug manufacturer, AbbVie focuses on creating innovative medicines for a wide range of therapeutic areas, including immunology, oncology, neuroscience, and aesthetics. The 'General' designation indicates that it produces a broad array of prescription drugs rather than specializing in a single niche, such as generic or biotech-only products. This industry positioning places AbbVie among major global pharmaceutical companies.

AbbVie Inc. has a diverse product portfolio spanning multiple therapeutic areas. In immunology, key products include Skyrizi for autoimmune diseases and Rinvoq for inflammatory conditions. In oncology, Imbruvica and Venclexta treat blood cancers, while Elahere and Emrelis address various solid tumors. For neuroscience, Vraylar is used for schizophrenia and bipolar disorder, Duodopa for Parkinson's, and Ubrelvy and Qulipta for migraine. AbbVie also offers Botox Therapeutic for chronic migraine, overactive bladder, and spasticity. In aesthetics, Botox Cosmetic and Juvederm Collection are popular for facial treatments and body contouring. Eye care products include Lumigan/Ganfort for glaucoma and Restasis for dry eye. Additionally, Mavyret treats hepatitis C, and Creon aids pancreatic enzyme deficiency.

AbbVie Inc. is headquartered in the United States and operates globally, serving markets worldwide. As a US-based company, it has a strong presence in North America, but its products are available in many countries across Europe, Asia, Latin America, and other regions. The company's global reach is evident from its description as developing, manufacturing, and commercializing medicines and therapies globally. AbbVie's international operations allow it to address diverse healthcare needs, from autoimmune and oncological conditions to aesthetic treatments, in various regulatory environments. Its headquarters location in the US also aligns with its primary listing on the NYSE and reporting in USD.